Peak Retirement Planning Inc. Makes New Investment in Insulet Co. (NASDAQ:PODD)

Peak Retirement Planning Inc. bought a new stake in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 4,070 shares of the medical instruments supplier's stock, valued at approximately $1,063,000.

A number of other institutional investors and hedge funds have also made changes to their positions in PODD. Baillie Gifford & Co. raised its holdings in Insulet by 3.5% in the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock valued at $614,998,000 after buying an additional 79,982 shares during the period. Geode Capital Management LLC increased its position in shares of Insulet by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier's stock worth $463,347,000 after acquiring an additional 40,566 shares in the last quarter. Norges Bank purchased a new position in shares of Insulet in the 4th quarter valued at $248,806,000. Artisan Partners Limited Partnership lifted its holdings in shares of Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock valued at $201,073,000 after acquiring an additional 149,524 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Insulet by 20.5% during the 4th quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock valued at $192,881,000 after acquiring an additional 125,710 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have commented on PODD shares. Raymond James raised their price objective on Insulet from $328.00 to $360.00 and gave the company an "outperform" rating in a research report on Tuesday. Wells Fargo & Company set a $322.00 target price on shares of Insulet in a research note on Monday, April 28th. Wall Street Zen downgraded shares of Insulet from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective on the stock in a report on Tuesday, May 13th. Finally, Oppenheimer raised their target price on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $309.88.

Insulet Stock Performance

NASDAQ:PODD traded up $5.28 during trading hours on Tuesday, reaching $326.64. 697,129 shares of the stock were exchanged, compared to its average volume of 708,680. The stock has a market capitalization of $22.99 billion, a P/E ratio of 56.41, a P/E/G ratio of 3.62 and a beta of 1.26. The firm has a 50 day simple moving average of $272.24 and a 200-day simple moving average of $270.26. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52 week low of $171.61 and a 52 week high of $333.75.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm's revenue for the quarter was up 28.8% on a year-over-year basis. During the same period last year, the business posted $0.73 earnings per share. As a group, sell-side analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP John W. Kapples sold 5,278 shares of the stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president now directly owns 23,180 shares in the company, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.